Oncology Today—June 2, 2026

This week’s Oncology update highlights precision-oncology momentum across regulatory reviews, FDA designations, reimbursement access, ASCO 2026 data, and earlier-line treatment settings in lung, bladder, colorectal, breast, pancreatic, nasopharyngeal, and gastrointestinal stromal tumors.

In Today’s Newsletter

Dive deeper

Ask Google AI

Ask ChatGPT

Ask Perplexity

Ask Grok

💸 BRAFTOVI gains Ontario FAST access in BRAF V600E mCRC [1] [Canada • 26 May 2026]

https://www.newswire.ca/news-releases/pfizer-s-braftovi-r-becomes-first-pfizer-therapy-to-receive-priority-access-under-ontario-s-fast-program-accelerating-treatment-for-canadians-with-metastatic-colorectal-cancer-811527520.html
Context: Pfizer Canada said BRAFTOVI (encorafenib) will be funded under Ontario’s Funding Accelerated for Specific Treatments program.
Key point: Ontario became the first province to fund BRAFTOVI for metastatic colorectal cancer with a BRAF V600E mutation, following a positive CDA-AMC reimbursement recommendation.
Implication: Could accelerate patient access and influence reimbursement pathways in other Canadian provinces.

🧬 ZEGFROVY gets China Priority Review in first-line EGFR ex20ins NSCLC [2] [China • 27 May 2026]

https://www.dizalpharma.com/news/detail?id=9e0981c56467444fb205512507a0dc8f&search=&currentPage=1
Context: ZEGFROVY (sunvozertinib, Dizal) is an irreversible EGFR inhibitor already approved in the US and China for previously treated EGFR exon 20 insertion-mutated NSCLC.
Key point: China’s NMPA CDE accepted and granted Priority Review to the NDA for first-line locally advanced or metastatic EGFR exon 20 insertion-mutated NSCLC, supported by WU-KONG28.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 RenovoRx receives FDA ODD for oxaliplatin in pancreatic cancer [3] [US • 28 May 2026]

https://ir.renovorx.com/news-events/press-releases/detail/164/renovorx-announces-fda-orphan-drug-designation-granted
Context: RenovoRx is developing targeted intra-arterial drug delivery using its RenovoCath device.
Key point: FDA granted Orphan Drug Designation to oxaliplatin for pancreatic cancer, the company’s second ODD in pancreatic cancer and third ODD overall.
Implication: Provides potential regulatory and financial incentives, including seven years of market exclusivity if approved.

🧪 Bezuclastinib NDA accepted with Priority Review in GIST [4] [US • 28 May 2026]

https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0
Context: Bezuclastinib plus sunitinib (Cogent Biosciences) was studied in PEAK Phase 3 for patients with GIST after prior imatinib.
Key point: FDA accepted the NDA, granted Priority Review, and set a PDUFA target action date of 30 Nov 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🧾 TEVIMBRA receives positive Canadian reimbursement recommendations in NPC [5] [Canada • 28 May 2026]

https://www.biospace.com/press-releases/beone-medicines-receives-positive-reimbursement-recommendations-from-cda-amc-and-inesss-for-tevimbra-in-first-line-nasopharyngeal-carcinoma
Context: TEVIMBRA (tislelizumab, BeOne Medicines) plus gemcitabine and cisplatin was assessed for recurrent or metastatic nasopharyngeal carcinoma.
Key point: CDA-AMC and INESSS issued positive reimbursement recommendations for first-line adult recurrent or metastatic NPC, following Health Canada approval in Dec 2025.
Implication: Could support broader public funding and improve access in Canada.

⏳ Camizestrant PDUFA extended for SERENA-6 review [6] [US, EU, global • 27 May 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html
Context: Camizestrant (AstraZeneca) is under FDA review with a CDK4/6 inhibitor for first-line HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation.
Key point: FDA extended the PDUFA date to review additional data, including ctDNA clearance analyses linked to longer-term efficacy outcomes; CHMP issued a positive opinion on 22 May.
Implication: Regulatory timing remains active across major markets, with interpretation linked to SERENA-6 and additional analyses.

🛡️ Imfinzi approved with BCG in high-risk NMIBC [7] [US • 28 May 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-approved-in-us-for-early-bladder-cancer.html
Context: Imfinzi (durvalumab, AstraZeneca) plus BCG induction and maintenance was tested in POTOMAC Phase 3.
Key point: FDA approved Imfinzi plus BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on a 32% reduction in risk of high-risk recurrence, progression, or death after one year.
Implication: May shift practice in a curative-intent bladder cancer setting.

🫁 Lunbotinib fumarate shows pivotal Phase 2 activity in RET fusion-positive NSCLC [8] [China, global • 29 May 2026]

https://www.prnewswire.com/news-releases/kelun-biotech-presents-pivotal-phase-ii-data-for-lunbotinib-fumarate-a400ep0031-in-ret-fusion-positive-nsclc-at-2026-asco-302786202.html?tc=eml_cleartime
Context: Lunbotinib fumarate (A400/EP0031, Kelun-Biotech) is a next-generation selective RET inhibitor.
Key point: Pivotal Phase 2 data showed confirmed ORR of 81.3% in treatment-naïve patients and 87.1% in pre-treated patients; China’s NMPA accepted the NDA for RET fusion-positive locally advanced or metastatic NSCLC.
Implication: Could inform practice and payer discussions; interpretation depends on study design and durability.

🎯 Calderasib gets FDA Breakthrough Therapy Designation in KRAS G12C NSCLC [9] [US • 29 May 2026]

https://www.merck.com/news/fda-grants-breakthrough-therapy-designation-for-calderasib-mk-1084-an-investigational-kras-g12c-inhibitor-for-certain-patients-with-newly-diagnosed-metastatic-kras-g12c-mutant-non-small-cell-lung/
Context: Calderasib (MK-1084, Merck; developed with Taiho and Astex/Otsuka) is an investigational oral KRAS G12C inhibitor being studied with Keytruda.
Key point: FDA granted Breakthrough Therapy Designation for first-line advanced or metastatic NSCLC with KRAS G12C mutation and PD-L1 TPS ≥1%, supported by Phase 1 KANDLELIT-001 data.
Implication: Signals pipeline investment and modality expansion in KRAS-targeted immunotherapy combinations.

🧬 Retevmo cuts recurrence or death risk in early RET fusion-positive NSCLC [10] [Global • 31 May 2026]

https://investor.lilly.com/news-releases/news-release-details/lillys-retevmo-selpercatinib-demonstrated-83-reduction-risk
Context: Retevmo (selpercatinib, Eli Lilly) was evaluated as adjuvant therapy in Phase 3 LIBRETTO-432 for early-stage RET fusion-positive NSCLC.
Key point: Retevmo reduced the risk of disease recurrence or death by 83% versus placebo in the primary analysis population.
Implication: Reinforces the role of comprehensive biomarker testing in earlier-stage NSCLC.

📊 PEAK Phase 3 details support bezuclastinib plus sunitinib in GIST [11] [Global • 30 May 2026]

https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-detailed-clinical-data-peak-phase-3
Context: Cogent presented detailed PEAK Phase 3 data for bezuclastinib plus sunitinib versus sunitinib in GIST after prior imatinib.
Key point: Median PFS was 16.5 months with the combination versus 9.2 months with sunitinib, with HR 0.50 and p<0.0001; benefit was reported regardless of primary or secondary KIT mutations.
Implication: Supports the regulatory case behind the FDA Priority Review and may shape launch readiness.

Why it matters

• Precision oncology dominated the week, with biomarker-defined updates across BRAF V600E mCRC, EGFR exon 20 insertion NSCLC, RET fusion-positive NSCLC, KRAS G12C NSCLC, ESR1-mutated breast cancer, and KIT-driven GIST.
• Regulatory acceleration remains active, including FDA Priority Review, FDA Breakthrough Therapy Designation, FDA Orphan Drug Designation, China NMPA Priority Review, and positive Canadian reimbursement recommendations.
• Earlier disease settings remain a major theme, including Imfinzi in BCG-naïve high-risk NMIBC, camizestrant’s first-line SERENA-6 strategy, and Retevmo in adjuvant early-stage RET fusion-positive NSCLC.
• Access and reimbursement were prominent, especially in Canada, where Ontario’s FAST program and TEVIMBRA reimbursement recommendations show post-approval market-access momentum.
• ASCO 2026 acted as a catalyst for clinical and regulatory narratives, especially for lunbotinib, Retevmo, camizestrant, and bezuclastinib.

📚 Discover the full Oncology archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.